Company Reaffirms Full-Year 2026 Guidance
Announces $150 Million Increase in Share Repurchase Authorization

MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) — Laureate Education, Inc. (NASDAQ: LAUR), which operates five higher education institutions across Mexico and Peru, today announced financial results for the third quarter and nine months ended September 30, 2026.

Third Quarter 2026 Highlights (compared to third quarter 2025):

  • On a reported basis, revenue increased 21% to $485.1 million. On a constant currency basis1, revenue increased 14% and was favorably affected by approximately $29 million of intra-year academic calendar timing attributable to semester start dates in 2026 as compared to 2025.
  • Operating income for the third quarter of 2026 was $119.1 million, compared to operating income of $71.5 million for the third quarter of 2025.
  • Net income for the third quarter of 2026 was $101.2 million, compared to net income of $34.4 million for the third quarter of 2025. The increase in net income compared to 2025 was mainly driven by higher operating income as well as a discrete tax benefit of $25.4 million that was recorded during the third quarter of 2026.
  • Adjusted EBITDA for the third quarter of 2026 was $146.8 million, compared to Adjusted EBITDA of $94.8 million for the third quarter of 2025. Adjusted EBITDA in the third quarter of 2026 was favorably affected by approximately $26 million of intra-year academic calendar timing attributable to semester start dates in 2026 as compared to 2025.

Nine Months Ended September 30, 2026 Highlights (compared to nine months ended September 30, 2025):

  • New enrollments increased 9%.
  • Total enrollments increased 6%.
  • On a reported basis, revenue increased 18% to $1,373.6 million. On a constant currency basis1, revenue increased 8% and was favorably affected by approximately $20 million of intra-year academic calendar timing attributable to semester start dates in the nine months ended September 30, 2026 as compared to the nine months ended September 30, 2025.
  • Operating income for the nine months ended September 30, 2026 was $315.0 million, compared to operating income of $251.6 million for the nine months ended September 30, 2025.
  • Net income for the nine months ended September 30, 2026 was $216.7 million, compared to net income of $112.3 million for the nine months ended September 30, 2025. The increase in net income was mainly driven by higher operating income as well as the effect of changes in foreign currency exchange rates on intercompany balances compared to the 2025 period, in addition to a discrete tax benefit of $25.4 million that was recorded during the nine months ended September 30, 2026.
  • Adjusted EBITDA for the nine months ended September 30, 2026 was $395.1 million, compared to Adjusted EBITDA of $314.7 million for the nine months ended September 30, 2025. Adjusted EBITDA for the nine months ended September 30, 2026 was favorably affected by approximately $17 million of intra-year academic calendar timing attributable to semester start dates in 2026 as compared to 2025.
  • Laureate expects that the intra-year academic calendar timing impacts on revenue and Adjusted EBITDA will be offset in the fourth quarter of 2026.

1 Constant currency results exclude the period-over-period impact from currency fluctuations.

Eilif Serck-Hanssen, President and Chief Executive Officer, said, “We are pleased to report strong new enrollment intakes in both of our markets. The primary intake in Mexico included a very successful launch of our new campus in Puebla, as well as further growth in existing campuses. During the secondary intake in Peru, we continued to leverage our fully online capabilities to meet growing demand for working adults as that market scales.”

Mr. Serck-Hanssen added, “Today we are announcing an additional $150 million increase to our share repurchase program, reflecting continued favorable operating momentum in the business, our strong balance sheet and commitment to returning capital to shareholders.”

Third Quarter 2026 Results

For the third quarter of 2026, revenue on a reported basis was $485.1 million, an increase of $84.9 million, or 21%, compared to the third quarter of 2025. On a constant currency basis, revenue increased 14% and was favorably affected by approximately $29 million of intra-year academic calendar timing attributable to semester start dates in 2026 as compared to 2025. Operating income for the third quarter of 2026 was $119.1 million, compared to $71.5 million for the third quarter of 2025, an increase of $47.6 million. Net income for the third quarter of 2026 was $101.2 million, compared to net income of $34.4 million for the third quarter of 2025. The increase in net income compared to 2025 was mainly driven by higher operating income as well as a discrete tax benefit of $25.4 million that was recorded during the third quarter of 2026. Basic and diluted earnings per share for the third quarter of 2026 were $0.74 and $0.73, respectively.

Adjusted EBITDA for the third quarter of 2026 was $146.8 million, compared to Adjusted EBITDA of $94.8 million for the third quarter of 2025. Adjusted EBITDA in the third quarter of 2026 was favorably affected by approximately $26 million of intra-year academic calendar timing attributable to semester start dates in 2026 as compared to 2025.

Nine Months Ended September 30, 2026 Results

New enrollments for the nine months ended September 30, 2026 increased 9%, compared to new enrollment activity for the nine months ended September 30, 2025, and total enrollments were up 6% compared to the prior-year period. New and total enrollments in Peru increased 10% and 5%, respectively, compared to the prior-year period. New and total enrollments in Mexico were up 8% and 6%, respectively, compared to the prior-year period.

For the nine months ended September 30, 2026, revenue on a reported basis was $1,373.6 million, an increase of $213.1 million, or 18%, compared to the nine months ended September 30, 2025. On a constant currency basis, revenue increased 8%. Revenue for the nine months ended September 30, 2026 was favorably affected by approximately $20 million of intra-year academic calendar timing attributable to semester start dates in 2026 as compared to 2025. Operating income for the nine months ended September 30, 2026 was $315.0 million, compared to $251.6 million for the nine months ended September 30, 2025, an increase of $63.4 million. Net income for the nine months ended September 30, 2026 was $216.7 million, compared to net income of $112.3 million for the nine months ended September 30, 2025. The increase in net income was mainly driven by higher operating income as well as the effect of changes in foreign currency exchange rates on intercompany balances compared to the 2025 period, in addition to a discrete tax benefit of $25.4 million that was recorded during the nine months ended September 30, 2026. Basic and diluted earnings per share for the nine months ended September 30, 2026 were $1.55 and $1.54, respectively.

Adjusted EBITDA for the nine months ended September 30, 2026 was $395.1 million, compared to Adjusted EBITDA of $314.7 million for the nine months ended September 30, 2025. Adjusted EBITDA for the nine months ended September 30, 2026 was favorably affected by approximately $17 million of intra-year academic calendar timing attributable to semester start dates in the 2026 period as compared to the 2025 period.

Balance Sheet and Capital Structure

As of September 30, 2026, Laureate had $189.9 million of cash and cash equivalents and gross debt of $204.2 million. Accordingly, net debt was $14.3 million as of September 30, 2026.

Laureate repurchased approximately $256 million of its common stock during the nine months ended September 30, 2026. As of September 30, 2026, Laureate had approximately $75.2 million of stock repurchase authorization remaining under its existing stock repurchase program. On October 29, 2026, the Company announced that its board of directors had approved a $150 million increase to its existing stock repurchase program to acquire shares of the Company’s common stock. After giving effect to this new authorization and taking into account the cumulative repurchases through September 30, 2026, the Company may repurchase up to approximately $225.2 million of its common stock under its stock repurchase program, which has no fixed expiration date.

As of September 30, 2026, Laureate had 135.7 million total shares outstanding.

Outlook for Fiscal 2026

Laureate is reaffirming its 2026 outlook.

Based on assumed foreign exchange rates2, Laureate expects its full-year 2026 results to be as follows:

  • Total enrollments are expected to be in the range of 518,000 to 523,000 students, reflecting growth of 4%-5% versus 2025;
  • Revenues are expected to be in the range of $1,920 million to $1,930 million, reflecting growth of 13% on an as-reported basis and growth of 6%-7% on a constant currency basis versus 2025;
  • Adjusted EBITDA is expected to be in the range of $593 million to $599 million, reflecting growth of 14%-15% on an as-reported basis and 8%-9% on a constant currency basis versus 2025; and
  • Adjusted EPS is expected to be in the range of $2.04 – $2.10 per share3, reflecting growth of 19%-22% on an as-reported basis versus 2025.

Reconciliations of forward-looking non-GAAP measures, specifically the outlook for 2026 Adjusted EBITDA and Adjusted EPS, to the relevant forward-looking GAAP measures are not being provided, as Laureate does not currently have sufficient data to accurately estimate the variables and individual adjustments for such outlooks and reconciliations. Due to this uncertainty, Laureate cannot reconcile projected Adjusted EBITDA and projected Adjusted EPS to projected net income and projected earnings per share, respectively, without unreasonable effort. Please see the “Forward-Looking Statements” section in this release for a discussion of certain risks related to this outlook.

Conference Call

Laureate will host an earnings conference call today at 8:30 am ET. Interested parties are invited to listen to the earnings call by registering at https://bit.ly/LAURQ32026 to receive dial-in information. The webcast of the conference call, including replays, and a copy of this press release and the related slides will be made available through the Investor Relations section of Laureate’s website at www.laureate.net.

2 Based on actual FX rates for January-October 2026, and assumed FX rates (local currency per U.S. Dollar) of MXN 18.60 and PEN 3.45 for November 2026 – December 2026. FX impact may change based on fluctuations in currency rates in future periods.

3 Assumes diluted weighted average shares outstanding of approximately 139 million.


Forward-Looking Statements

This press release includes statements that express Laureate’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, ‘‘forward-looking statements’’ within the meaning of the federal securities laws, which involve risks and uncertainties. Laureate’s actual results may vary significantly from the results anticipated in these forward-looking statements. You can identify forward-looking statements because they contain words such as ‘‘believes,’’ ‘‘expects,’’ ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘seeks,’’ ‘‘approximately,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘estimates’’ or ‘‘anticipates’’ or similar expressions that concern our strategy, plans or intentions. In particular, statements regarding the amount, timing, process, tax treatment and impact of any future dividends represent forward-looking statements. All statements we make relating to guidance (including, but not limited to, total enrollments, revenues, Adjusted EBITDA and Adjusted EPS), and all statements we make relating to our current growth strategy and other future plans, strategies or transactions that may be identified, explored or implemented and any litigation or dispute resulting from any completed transaction are forward-looking statements. In addition, we, through our senior management, from time to time make forward-looking public statements concerning our expected future operations and performance and other developments. All of these forward-looking statements are subject to risks and uncertainties that may change at any time, including with respect to our current growth strategy and the impact of any completed divestiture or separation transaction on our remaining businesses. Accordingly, our actual results may differ materially from those we expected. We derive most of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations are disclosed in our Annual Report on Form 10-K filed with the SEC on February 19, 2026, our subsequent Quarterly Reports on Form 10-Q filed, and to be filed, with the SEC and other filings made with the SEC. These forward-looking statements speak only as of the time of this release and we do not undertake to publicly update or revise them, whether as a result of new information, future events or otherwise, except as required by law.

Presentation of Non-GAAP Measures

In addition to the results provided in accordance with U.S. generally accepted accounting principles (GAAP) throughout this press release, Laureate provides the non-GAAP measurements of Adjusted EBITDA, Adjusted net income, Adjusted EPS, and total debt, net of cash and cash equivalents (or net debt). We have included the non-GAAP measures of Adjusted EBITDA and net debt because they are key measures used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget and to develop short- and long-term operational plans. We have included the non-GAAP measures of Adjusted net income and Adjusted EPS because management believes that these measures provide investors with better visibility into Laureate’s underlying earnings as they exclude items that may not be indicative of our core operating results.

Adjusted EBITDA consists of net income (loss), before (income) loss from discontinued operations, net of tax, equity in net (income) loss of affiliates, net of tax, income tax expense (benefit), (gain) loss on disposal of subsidiaries, net, foreign currency exchange (gain) loss, net, other (income) expense, net, interest expense, interest income, and loss on debt extinguishment, plus depreciation and amortization, share-based compensation expense, and loss on impairment of assets. The exclusion of certain expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Additionally, Adjusted EBITDA is a key input into the formula used by the compensation committee of our board of directors and our Chief Executive Officer in connection with the payment of incentive compensation to our executive officers and other members of our management team. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

We define Adjusted net income as net income (loss), before (income) loss from discontinued operations, plus discrete tax items, loss on debt extinguishment, loss (gain) on disposal of subsidiaries, net, foreign currency exchange (gain) loss, net, and loss on impairment of assets. We define Adjusted EPS as Adjusted net income divided by GAAP diluted weighted average shares outstanding. Adjusted net income and Adjusted EPS provide a useful indicator about Laureate’s earnings from core operations.

Total debt, net of cash and cash equivalents, (or net debt) consists of total gross debt less total cash and cash equivalents. Net debt provides a useful indicator about Laureate’s leverage and liquidity.

Free Cash Flow consists of operating cash flow minus capital expenditures (net of sales of PP&E). Free Cash Flow provides a useful indicator about Laureate’s ability to fund its operations and repay its debt.

Adjusted EBITDA to Unlevered Free Cash Flow Conversion consists of Unlevered Free Cash Flow (which is defined as cash flows from operating activities, less capital expenditures (net of sales of PP&E), plus net cash interest expense) divided by Adjusted EBITDA. Adjusted EBITDA to Unlevered Free Cash Flow provides useful information to investors and others in understanding and evaluating our ability to generate cash flows.

Laureate’s calculations of Adjusted EBITDA, Adjusted net income, Adjusted EPS, and total debt, net of cash and cash equivalents (or net debt) are not necessarily comparable to calculations performed by other companies and reported as similarly titled measures. These non-GAAP measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results. Adjusted EBITDA, Adjusted net income and Adjusted EPS are reconciled from their most directly comparable GAAP measures in the attached tables under “Non-GAAP Reconciliations.”

We evaluate our results of operations on both an as reported and a constant currency basis. The constant currency presentation, which is a non-GAAP measure, excludes the impact of fluctuations in foreign currency exchange rates. We believe that providing constant currency information provides valuable supplemental information regarding our results of operations, consistent with how we evaluate our performance. We calculate constant currency amounts using the change from prior-period average foreign exchange rates to current-period average foreign exchange rates, as applied to local-currency operating results for the current period.

About Laureate Education, Inc.

Laureate Education, Inc. operates five higher education institutions across Mexico and Peru, enrolling more than 500,000 students in high-quality undergraduate, graduate, and specialized degree programs through campus-based and online learning. Our universities have a deep commitment to academic quality and innovation, strive for market-leading employability outcomes, and work to make higher education more accessible. At Laureate, we know that when our students succeed, countries prosper, and societies benefit. Learn more at laureate.net.

Key Metrics and Financial Tables
(Dollars in millions, except per share amounts, and may not sum due to rounding)

New and Total Enrollments by segment

  New Enrollments   Total Enrollments
  YTD 3Q 2026   YTD 3Q 2025   Change   As of 09/30/2026   As of 09/30/2025   Change
Mexico 171,000   158,000   8 %   292,500   277,000   6 %
Peru 110,800   100,800   10 %   247,100   234,400   5 %
Laureate 281,800   258,800   9 %   539,600   511,400   6 %
                           

Consolidated Statements of Operations

  For the three months ended September 30,   For the nine months ended September 30,
IN MILLIONS (except per share amounts)   2026       2025     Change     2026       2025     Change
Revenues $ 485.1     $ 400.2     $ 84.9     $ 1,373.6     $ 1,160.5     $ 213.1  
Costs and expenses:                      
Direct costs   353.4       316.5       36.9       1,020.6       872.3       148.3  
General and administrative expenses   12.6       12.2       0.4       37.9       36.7       1.2  
Operating income   119.1       71.5       47.6       315.0       251.6       63.4  
Interest income   2.3       2.1       0.2       5.7       5.0       0.7  
Interest expense   (4.8 )     (2.6 )     (2.2 )     (12.1 )     (8.1 )     (4.0 )
Other income, net   (0.1 )     0.2       (0.3 )     0.4       1.0       (0.6 )
Foreign currency exchange loss, net   4.7       (2.3 )     7.0       3.7       (31.1 )     34.8  
Income from continuing operations before income taxes   121.2       68.8       52.4       312.7       218.4       94.3  
Income tax expense   (20.0 )     (34.5 )     14.5       (96.0 )     (106.3 )     10.3  
Income from continuing operations   101.2       34.4       66.8       216.7       112.0       104.7  
Income from discontinued operations, net of tax   —       —       —       —       0.2       (0.2 )
Net income   101.2       34.4       66.8       216.7       112.3       104.4  
Net income attributable to noncontrolling interests   —       0.1       (0.1 )     —       (2.2 )     2.2  
Net income attributable to Laureate Education, Inc. $ 101.2     $ 34.5     $ 66.7     $ 216.7     $ 110.1     $ 106.6  

Basic and diluted earnings per share:                      
Basic weighted average shares outstanding   137.2     147.4     (10.2 )     139.5     148.5     (9.0 )
Diluted weighted average shares outstanding   138.0     148.2     (10.2 )     140.4     149.2     (8.8 )
Basic earnings per share $ 0.74   $ 0.23   $ 0.51     $ 1.55   $ 0.74   $ 0.81  
Diluted earnings per share $ 0.73   $ 0.23   $ 0.50     $ 1.54   $ 0.74   $ 0.80  
                                       

Revenue and Adjusted EBITDA by segment

IN MILLIONS

          % Change   $ Variance Components
For the three months ended September 30,   2026       2025     Reported   Constant
Currency(1)
  Total   Constant
Currency
  FX
Revenues                          
Mexico $ 256.5     $ 194.8     32 %   22 %   $ 61.7     $ 42.4     $ 19.3
Peru   228.6       205.3     11 %   7 %     23.3       13.4       9.9
Corporate & Eliminations   —       —     nm   nm     —       —       —
Total Revenues $ 485.1     $ 400.2     21 %   14 %   $ 84.9     $ 55.9     $ 29.2
                           
Adjusted EBITDA                          
Mexico $ 62.1     $ 25.7     142 %   123 %   $ 36.4     $ 31.7     $ 4.7
Peru   94.0       78.1     20 %   15 %     15.9       11.8       4.1
Corporate & Eliminations   (9.2 )     (8.9 )   (3 )%   (3 )%     (0.3 )     (0.3 )     —
Total Adjusted EBITDA $ 146.8     $ 94.8     55 %   46 %   $ 52.0     $ 43.2     $ 8.8

          % Change   $ Variance Components
For the nine months ended September 30,   2026       2025     Reported   Constant
Currency(1)
  Total   Constant
Currency
  FX
Revenues                          
Mexico $ 736.1     $ 601.5     22 %   9 %   $ 134.6     $ 55.8     $ 78.8
Peru   637.4       558.9     14 %   8 %     78.5       42.2       36.3
Corporate & Eliminations   —       0.1     (100 )%   (100 )%     (0.1 )     (0.1 )     —
Total Revenues $ 1,373.6     $ 1,160.5     18 %   8 %   $ 213.1     $ 98.0     $ 115.1
                           
Adjusted EBITDA                          
Mexico $ 174.1     $ 136.1     28 %   14 %   $ 38.0     $ 19.1     $ 18.9
Peru   249.8       206.5     21 %   15 %     43.3       30.7       12.6
Corporate & Eliminations   (28.9 )     (27.9 )   (4 )%   (4 )%     (1.0 )     (1.0 )     —
Total Adjusted EBITDA $ 395.1     $ 314.7     26 %   16 %   $ 80.4     $ 48.8     $ 31.5
nm – percentage changes not meaningful

(1) Constant Currency results exclude the period-over-period impact from currency fluctuations. Constant Currency is calculated using the change from prior-period average foreign exchange rates to current-period average foreign exchange rates, as applied to local-currency operating results for the current period. The “Constant Currency” percentage changes are calculated by dividing the Constant Currency amounts by the 2025 Revenues and Adjusted EBITDA amounts.

                                                 

Consolidated Balance Sheets

IN MILLIONS September 30, 2026   December 31, 2025   Change
Assets          
Cash and cash equivalents $ 189.9   $ 146.7   $ 43.2  
Receivables (current), net   117.7     134.7     (17.0 )
Other current assets   39.9     36.9     3.0  
Property and equipment, net   658.0     628.6     29.4  
Operating lease right-of-use assets, net   532.8     335.6     197.2  
Goodwill and other intangible assets   808.2     803.5     4.7  
Deferred income taxes   79.1     72.2     6.9  
Other long-term assets   51.3     46.4     4.9  
Current and long-term assets held for sale   0.8     1.7     (0.9 )
Total assets $ 2,477.6   $ 2,206.4   $ 271.2  
           
Liabilities and stockholders’ equity          
Accounts payable and accrued expenses $ 258.2   $ 242.4   $ 15.8  
Deferred revenue and student deposits   110.2     80.2     30.0  
Total operating leases, including current portion   579.9     387.8     192.1  
Total long-term debt, including current portion   202.7     127.7     75.0  
Other liabilities   166.4     179.6     (13.2 )
Total liabilities   1,317.4     1,017.6     299.8  
Redeemable equity   0.7     1.4     (0.7 )
Total stockholders’ equity   1,159.5     1,187.4     (27.9 )
Total liabilities and stockholders’ equity $ 2,477.6   $ 2,206.4   $ 271.2  
                   

Consolidated Statements of Cash Flows

  For the nine months ended September 30,
IN MILLIONS   2026       2025     Change
Cash flows from operating activities          
Net income $ 216.7     $ 112.3     $ 104.4  
Depreciation and amortization   69.4       53.3       16.1  
Gain on lease terminations and disposals of subsidiaries and property and equipment, net   (1.2 )     (0.3 )     (0.9 )
Deferred income taxes   (6.3 )     —       (6.3 )
Unrealized foreign currency exchange loss   (3.9 )     30.9       (34.8 )
Income tax receivable/payable, net   (26.4 )     5.2       (31.6 )
Working capital, excluding tax accounts   (1.5 )     (0.6 )     (0.9 )
Other non-cash adjustments   77.8       72.0       5.8  
Net cash provided by operating activities   324.6       272.8       51.8  
Cash flows from investing activities          
Purchase of property and equipment   (63.4 )     (36.1 )     (27.3 )
Receipts from sales of property and equipment   2.4       0.2       2.2  
Net receipts from sales of discontinued operations   —       0.1       (0.1 )
Net cash used in investing activities   (61.0 )     (35.7 )     (25.3 )
Cash flows from financing activities          
Increase in long-term debt, net   42.6       (22.6 )     65.2  
Payments to repurchase common stock and excise tax payments   (258.9 )     (71.6 )     (187.3 )
Financing other, net   (5.2 )     (2.7 )     (2.5 )
Net cash used in financing activities   (221.5 )     (96.9 )     (124.6 )
Effects of exchange rate changes on Cash and cash equivalents and Restricted cash   (0.1 )     8.1       (8.2 )
Change in cash included in current assets held for sale   —       0.3       (0.3 )
Net change in Cash and cash equivalents and Restricted cash   42.0       148.6       (106.6 )
Cash and cash equivalents and Restricted cash at beginning of period   152.1       97.9       54.2  
Cash and cash equivalents and Restricted cash at end of period $ 194.0     $ 246.4     $ (52.4 )
                       

Non-GAAP Reconciliation (1 of 3)

The following table reconciles Net income to Adjusted EBITDA:

  For the three months ended September 30,   For the nine months ended September 30,
IN MILLIONS   2026       2025     Change     2026       2025     Change
Net income $ 101.2     $ 34.4     $ 66.8     $ 216.7     $ 112.3     $ 104.4  
Plus:                      
Loss from discontinued operations, net of tax   —       —       —       —       (0.2 )     0.2  
Income from continuing operations   101.2       34.4       66.8       216.7       112.0       104.7  
Plus:                      
Income tax expense   20.0       34.5       (14.5 )     96.0       106.3       (10.3 )
Income from continuing operations before income taxes   121.2       68.8       52.4       312.7       218.4       94.3  
Plus:                      
Foreign currency exchange (gain) loss, net   (4.7 )     2.3       (7.0 )     (3.7 )     31.1       (34.8 )
Other expense (income), net   0.1       (0.2 )     0.3       (0.4 )     (1.0 )     0.6  
Interest expense   4.8       2.6       2.2       12.1       8.1       4.0  
Interest income   (2.3 )     (2.1 )     (0.2 )     (5.7 )     (5.0 )     (0.7 )
Operating income   119.1       71.5       47.6       315.0       251.6       63.4  
Plus:                      
Depreciation and amortization   23.8       19.6       4.2       69.4       53.3       16.1  
EBITDA   142.9       91.1       51.8       384.4       304.9       79.5  
Plus:                      
Share-based compensation expense(1)   3.9       3.8       0.1       10.6       9.7       0.9  
Adjusted EBITDA $ 146.8     $ 94.8     $ 52.0     $ 395.1     $ 314.7     $ 80.4  
(1) Represents non-cash, share-based compensation expense pursuant to the provisions of ASC Topic 718, “Stock Compensation.”
 

Non-GAAP Reconciliations (2 of 3)

The following table reconciles Net income to Adjusted net income and Adjusted EPS:

  For the three months ended September 30,  
    2026       2025  
IN MILLIONS, except per share amounts     (per share)(1)
        (per share)(1)
 
Net income $ 101.2     $ 0.73     $ 34.4   $ 0.23  
Plus:                
Income from discontinued operations, net of tax   —       —       —     —  
Income from continuing operations   101.2       0.73       34.4     0.23  
Plus:                
Discrete tax items(2)   (24.8 )     (0.18 )     1.8     0.01  
Loss on debt extinguishment   —       —       —     —  
Loss on disposal of subsidiaries, net   —       —       —     —  
Foreign currency exchange loss, net   (4.7 )     (0.03 )     2.3     0.02  
Loss on impairment of assets   —       —       —     —  
Adjusted net income $ 71.7     $ 0.52     $ 38.5   $ 0.26  
                 
Diluted weighted average shares outstanding       138.0           148.2  
(1)   Per share amounts on a dilutive basis. Earnings per share is calculated based on income available to common shareholders, which excludes income attributable to noncontrolling interests.
(2) Discrete tax items for 2026 represent a non-recurring, non-cash income tax benefit of approximately $25.4 million that was recorded upon resolution of a legacy tax contingency, partially offset by $0.6 million of interest expense related to legacy tax liabilities.

Beginning in the fourth quarter of 2025, Laureate determined that the interest related to certain legacy tax liabilities, which is recorded as a component of income tax (benefit) expense and totaled $0.6 million and $1.8 million for the three months ended September 30, 2026 and 2025, respectively, should be excluded from Adjusted net income and treated as a discrete tax item as this provides a more useful indicator of Laureate’s earnings from core operations. For comparability and to conform the prior year to the current presentation, Laureate has revised the 2025 amount for discrete tax items by $1.8 million to adjust for the interest related to these legacy tax liabilities that was recorded during the three months ended September 30, 2025.

 

Non-GAAP Reconciliations (3 of 3)

The following table reconciles Net income to Adjusted net income and Adjusted EPS:

  For the nine months ended September 30,  
    2026       2025  
IN MILLIONS, except per share amounts     (per share)(1)
        (per share)(1)  
Net income $ 216.7     $ 1.54     $ 112.3     $ 0.74  
Plus:                
Loss from discontinued operations, net of tax   —       —       (0.2 )     —  
Income from continuing operations   216.7       1.54       112.0       0.74  
Plus:                
Discrete tax items(2)   (25.4 )     (0.18 )     0.8       0.01  
Loss on debt extinguishment   —       —       —       —  
Loss on disposal of subsidiaries, net   —       —       —       —  
Foreign currency exchange loss, net   (3.7 )     (0.03 )     31.1       0.21  
Loss on impairment of assets   —       —       —       —  
Adjusted net income $ 187.6     $ 1.33     $ 143.9     $ 0.96  
                 
Diluted weighted average shares outstanding       140.4           149.2  
(1)   Per share amounts on a dilutive basis. Earnings per share is calculated based on income available to common shareholders, which excludes income attributable to noncontrolling interests.
(2)   Discrete tax items for 2026 include a non-recurring, non-cash income tax benefit of approximately $25.4 million that was recorded upon resolution of a legacy tax contingency. Discrete tax items for 2025 include $5.5 million of interest expense related to legacy tax liabilities, partially offset by a non-recurring, non-cash income tax benefit of approximately $4.7 million that was recorded upon resolution of a tax contingency related to a dormant subsidiary.

Beginning in the fourth quarter of 2025, Laureate determined that the interest related to certain legacy tax liabilities, which is recorded as a component of income tax (benefit) expense, should be excluded from Adjusted net income and treated as a discrete tax item as this provides a more useful indicator of Laureate’s earnings from core operations. For comparability and to conform the prior year to the current presentation, Laureate has revised the 2025 amount for discrete tax items by $5.5 million to adjust for the interest related to these legacy tax liabilities that was recorded during the nine months ended September 30, 2025.

 

Investor Relations Contact:

ir@laureate.net

Media Contacts:

Laureate Education    
Adam Smith    
adam.smith@laureate.net    
U.S.: +1 (443) 255 0724    
Source: Laureate Education, Inc.    

WAYNE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will report its third quarter 2026 financial results before market open on Thursday, November 5, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.

To access the live webcast, including presentation slides, please click here or visit the “Events & Presentations” section of Palvella’s website. To access the conference call by phone, register using this link, and you will be provided with dial-in details. A replay of the webcast will be available approximately two hours after the conclusion of the call and will remain archived for 90 days under the “Events & Presentations” section of the Company’s website at www.palvellatx.com.

About Palvella Therapeutics

Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular anomalies for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular anomalies, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors

Wesley H. Kaupinen
Founder and CEO
Palvella Therapeutics
wes.kaupinen@palvellatx.com

Media

Marcy Nanus
Vice President, Investor Relations and Corporate Affairs
Palvella Therapeutics
marcy.nanus@palvellatx.com

Third quarter 2026 Service revenue grew 26% compared to the third quarter 2025

LUXEMBOURG, Oct. 29, 2026 (GLOBE NEWSWIRE) — Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider and marketplace for the real estate and mortgage industries, today reported financial results for the third quarter 2026.

“We are pleased with our third quarter 2026 performance, with year-over-year Service revenue and Adjusted EBITDA growth in both segments. Customer wins continued to ramp, driving a 26% increase in total Company Service revenue, while revenue from customers outside of Onity and Rithm grew 96% year over year and now represents 72% of our Service revenue. Additionally, our AI and other efficiency initiatives began accelerating product development speed and are anticipated to drive scalability and operating leverage over the upcoming quarters,” said William B. Shepro, Chairman and Chief Executive Officer.

Mr. Shepro further commented, “Together, the continued ramp and seasoning of customer wins, greater operating leverage and disciplined cost management represent the core building blocks of Project 45—our objective of reaching $45 million of run-rate Adjusted EBITDA by the fourth quarter of 2028.”

Third Quarter 2026 Highlights(2)

Company, Corporate and Financial:

  • Third quarter Service revenue of $49.8 million was $10.2 million, or 26%, higher than the same quarter of 2025
  • Third quarter Loss before income taxes and non-controlling interests of $(993) thousand decreased by $0.7 million compared to the same quarter of 2025
  • Third quarter Net loss attributable to Altisource of $(1.4) million improved by $1.0 million compared to the same quarter of 2025
  • Third quarter Diluted loss per share of $(0.12) improved by $0.10 compared to the same quarter of 2025
  • Third quarter Adjusted diluted earnings per share(1) of $0.13 improved by $0.03, or 30%, compared to the same quarter of 2025
  • Third quarter Adjusted earnings before interest, tax, depreciation and amortization (“Adjusted EBITDA”)(1) of $4.3 million was $0.6 million, or 17%, higher than the same quarter of 2025
  • Third quarter Adjusted EBITDA(1) margin of 8.5% declined modestly from 9.1% in the same quarter of 2025 from revenue mix changes and continued investment in current and future growth, largely offset by stable corporate costs on growing revenue
  • The Company recognized a $1.0 million gain on early extinguishment of debt for the nine months ended September 30, 2026 from second and third quarter 2026 repurchases of $2.0 million and $0.9 million, respectively, of debt under the New Facility, both at a discount of 23.7% (no comparable amount for the nine months ended September 30, 2025)
  • Third quarter Cash provided by operating activities of $3.5 million was a $2.8 million increase, compared to the same quarter of 2025, almost all of which was driven by the improvement in net loss attributable to Altisource; we ended the quarter with $25.1 million of cash and cash equivalents

Business and Industry:

  • Adjusted EBITDA(1) in the Servicer and Real Estate and Origination segments (together “Business Segments”) was $11.3 million, or 22.8% of Service revenue, compared to $10.9 million, or 27.5% of Service revenue, in the same quarter of 2025 primarily due to increased Service revenue period over period, revenue mix changes and continued investment in current and future growth
  • Generated sales wins which we estimate represent potential annualized service revenue on a stabilized basis of $2.7 million for the Servicer and Real Estate segment and $6.3 million for the Origination segment
  • Driven by recent sales wins, total Hubzu inventory grew 16% since the second quarter 2026 and more than quadrupled since September 30, 2025
               
  (in thousands)(6)   September 30, 2025   June 30,
2026
  September 30,
2026
  Foreclosure Auction Inventory(5)   4.0   19.3   22.9
  REO Inventory – Customers other than Rithm   0.7   2.6   2.8
  REO Inventory – Rithm   1.0   0.4   0.2
  Total Hubzu Inventory   5.7   22.3   26.0
               
  • Ended the quarter with an estimated weighted average sales pipeline between $27.8 million and $34.7 million of potential estimated annual revenue on a stabilized basis based upon forecasted probability of closing (comprising of between $11.4 million and $14.2 million in the Servicer and Real Estate segment and between $16.4 million and $20.6 million in the Origination segment)
  • Industrywide foreclosure initiations were 20% higher for the eight months ended August 31, 2026 compared to the same period in 2025 (although still 6% lower than the same pre-COVID-19 period in 2019)(3)
  • Industrywide foreclosure sales were 17% higher for the eight months ended August 31, 2026 compared to the same period in 2025 (although still 40% lower than the same pre-COVID-19 period in 2019)(3)
  • Industrywide mortgage origination unit volume decreased by 6% for the third quarter 2026 compared to the same period in 2025, comprised of a 5% decrease in purchase origination unit volume and an 8% decrease in refinancing origination unit volume(4)

Third Quarter 2026 Financial Results

  • Service revenue of $49.8 million
  • Income from operations of $0.8 million
  • Loss before income taxes and non-controlling interests of $(993) thousand
  • Net loss attributable to Altisource of $(1.4) million
  • Adjusted EBITDA(1) of $4.3 million
  • Diluted loss per share of $(0.12)
  • Adjusted diluted earnings per share(1) of $0.13

Third Quarter 2026 Results Compared to the Third Quarter 2025 (unaudited):

(in thousands, except per share data) Third Quarter 2026   Third Quarter 2025   % Change   Year-to-Date September 30, 2026   Year-to-Date September 30, 2025   % Change
Service revenue $ 49,847     $ 39,666     26   $ 143,666     $ 121,348     18  
Revenue   51,920       41,908     24     150,167       128,635     17  
Gross profit   12,124       11,347     7     38,055       37,699     1  
Income from operations   764       521     47     3,620       6,997     (48 )
Adjusted operating income(1)   3,845       2,663     44     11,814       13,297     (11 )
Loss before income taxes and non-controlling interests   (993 )     (1,665 )   40     (680 )     (6,007 )   89  
Pretax loss attributable to Altisource(1)   (993 )     (1,736 )   43     (831 )     (6,227 )   87  
Adjusted pretax income attributable to Altisource(1)   2,088       1,312     59     7,363       4,431     66  
Adjusted EBITDA(1)   4,252       3,621     17     13,107       14,265     (8 )
Net (loss) income attributable to Altisource   (1,399 )     (2,396 )   42     (2,596 )     8,842     (129 )
Adjusted net income attributable to Altisource(1)   1,520       1,092     39     5,646       3,115     81  
Diluted (loss) earnings per share   (0.12 )     (0.22 )   45     (0.23 )     0.81     (128 )
Adjusted diluted earnings per share(1)   0.13       0.10     30     0.48       0.29     66  
Net cash provided by (used in) operating activities   3,482       718     385     1,305       (4,560 )   129  
Net cash provided by (used in) operating activities less additions to premises and equipment(1)   2,912       697     318     366       (4,609 )   108  
                       
Margins:                      
Gross profit / service revenue   24 %     29 %         26 %     31 %    
Adjusted EBITDA(1)/ service revenue   9 %     9 %         9 %     12 %    
                       
N/M – not meaningful                      
  • For the three and nine months ended September 30, 2026, loss before income taxes and non-controlling interests includes $0.3 million and $1.0 million, respectively, of gain on early extinguishment of debt (no comparative amount for the three or nine month period ended September 30, 2025)
  • For the three and nine months ended September 30, 2025, loss before income taxes and non-controlling interests includes $0.2 million and $3.6 million, respectively, of Debt Exchange Transaction expenses (no comparative amount for three or nine month period ended September 30, 2026)
  • For the nine months ended September 30, 2025, net income attributable to Altisource includes an $18.5 million income tax benefit related to the reversal of a portion of its reserves for uncertain India tax positions and related accrued interest (no comparable amount for the nine months ended September 30, 2026).

________________________

(1) This is a non-GAAP measure that is defined and reconciled to the corresponding GAAP measure herein
(2) Applies to the third quarter 2026 unless otherwise indicated
(3) Based on data from ICE’s Mortgage Monitor and First Look reports with data through August 2026
(4) Based on estimated number of loans originated as reported by the Mortgage Bankers Association’s Mortgage Finance Forecast dated October 11, 2026
(5) Altisource does not provide foreclosure auction services to Rithm
(6) Numbers may not sum due to rounding


Forward-Looking Statements

This press release contains forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements include all statements that are not historical fact, including statements that relate to, among other things, future events or our future financial / operating performance or financial condition. These statements may be identified by words such as “anticipate,” “intend,” “expect,” “may,” “could,” “should,” “would,” “will,” “plan,” “estimate,” “seek,” “believe,” “potential”, “positioned” or “continue” or the negative of these terms and comparable terminology. Such statements are based on expectations as to the future and are not statements of historical fact. Furthermore, forward-looking statements are not guarantees of future performance and involve a number of assumptions, risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ materially from those suggested by the forward-looking statements include, but are not limited to, the risks discussed in Item 1A of Part I “Risk Factors” in our Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 4, 2026, our Form 10-Q filed with the SEC on July 23, 2026 and our Form 10-Q filed with the SEC on October 29, 2026. We caution you not to place undue reliance on these forward-looking statements which reflect our view only as of the date of this report. We are under no obligation (and expressly disclaim any obligation) to update or alter any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or change in events, conditions or circumstances on which any such statement is based. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, risks related to customer concentration, impacts to default related referrals occasioned by government, investor or servicer actions, the use and success of our products and services, our ability to retain existing customers and attract new customers and the potential for expansion or changes in our customer relationships, technology disruptions, our compliance with applicable data requirements, our use of third party vendors and contractors, our ability to effectively manage potential conflicts of interest, macro-economic and industry specific conditions, our ability to effectively manage our regulatory and contractual obligations, the adequacy of our financial resources, including our sources of liquidity and ability to repay borrowings and comply with our debt agreements, including the financial and other covenants contained therein, as well as Altisource’s ability to retain key executives or employees, behavior of customers, suppliers and/or competitors, technological developments, governmental regulations, taxes and policies. The financial projections and scenarios contained in this press release are expressly qualified as forward-looking statements and, as with other forward-looking statements, should not be unduly relied upon. We undertake no obligation to update these statements, scenarios and projections as a result of a change in circumstances, new information or future events, except as required by law.

Webcast

Altisource will host a webcast at 08:30 a.m. EDT today to discuss our third quarter. A link to the live audio webcast will be available on Altisource’s website in the Investor Relations section. Those who want to listen to the call should go to the website at least fifteen minutes prior to the call to register, download and install any necessary audio software. A replay of the conference call will be available via the website approximately two hours after the conclusion of the call and will remain available for approximately 30 days.

About Altisource®

Altisource Portfolio Solutions S.A. is an integrated service provider and marketplace for the real estate and mortgage industries. Combining operational excellence with a suite of innovative services and technologies, Altisource helps solve the demands of the ever-changing markets it serves. Additional information is available at www.altisource.com.

         
ALTISOURCE PORTFOLIO SOLUTIONS S.A.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
(in thousands, except per share data)
(unaudited)
         
    Three months ended
September 30,
  Nine months ended
September 30,
      2026       2025       2026       2025  
                 
Service revenue   $ 49,847     $ 39,666     $ 143,666     $ 121,348  
Reimbursable expenses     2,073       2,171       6,350       7,067  
Non-controlling interests     —       71       151       220  
Total revenue     51,920       41,908       150,167       128,635  
Cost of revenue     39,796       30,561       112,112       90,936  
Gross profit     12,124       11,347       38,055       37,699  
Selling, general and administrative expenses     11,360       10,826       34,435       30,702  
Income from operations     764       521       3,620       6,997  
Other income (expense), net:                
Interest expense     (2,157 )     (2,368 )     (6,395 )     (9,921 )
Gain on early extinguishment of debt     312       —       1,008       —  
Debt exchange transaction expenses     —       (194 )     —       (3,646 )
Other income (expense), net     88       376       1,087       563  
Total other income (expense), net     (1,757 )     (2,186 )     (4,300 )     (13,004 )
                 
Loss before income taxes and non-controlling interests     (993 )     (1,665 )     (680 )     (6,007 )
Income tax (provision) benefit     (406 )     (660 )     (1,765 )     15,069  
                 
Net (loss) income     (1,399 )     (2,325 )     (2,445 )     9,062  
Net income attributable to non-controlling interests     —       (71 )     (151 )     (220 )
                 
Net (loss) income attributable to Altisource   $ (1,399 )   $ (2,396 )   $ (2,596 )   $ 8,842  
                 
(Loss) earnings per share:                
Basic   $ (0.12 )   $ (0.22 )   $ (0.23 )   $ 0.91  
Diluted   $ (0.12 )   $ (0.22 )   $ (0.23 )   $ 0.81  
                 
Weighted average shares outstanding:                
Basic     11,422       10,988       11,294       9,755  
Diluted     11,422       10,988       11,294       10,890  
                 
Comprehensive (loss) income:                
Comprehensive (loss) income, net of tax   $ (1,399 )   $ (2,325 )   $ (2,445 )   $ 9,062  
Comprehensive income attributable to non-controlling interests     —       (71 )     (151 )     (220 )
                 
Comprehensive (loss) income attributable to Altisource   $ (1,399 )   $ (2,396 )   $ (2,596 )   $ 8,842  

       
ALTISOURCE PORTFOLIO SOLUTIONS S.A.
CONSOLIDATED BALANCE SHEETS
(in thousands, except for per share data)
(unaudited)
       
  September 30,
2026
  December 31,
2025
       
ASSETS
Current assets:      
Cash and cash equivalents $ 25,055     $ 26,603  
Accounts receivable, net of allowance for credit losses of $1,984 and $2,492, respectively   26,670       17,984  
Prepaid expenses and other current assets   6,140       9,690  
Total current assets   57,865       54,277  
       
Premises and equipment, net   990       253  
Right-of-use assets under operating leases   612       1,117  
Goodwill   55,960       55,960  
Intangible assets, net   12,870       17,085  
Deferred tax assets, net   6,218       6,342  
Other assets   2,198       4,767  
       
Total assets $ 136,713     $ 139,801  
       
LIABILITIES AND DEFICIT
Current liabilities:      
Accounts payable and accrued expenses $ 46,296     $ 39,595  
Current portion of long-term debt   1,225       1,225  
Deferred revenue   2,746       3,440  
Other current liabilities   1,467       2,805  
Total current liabilities   51,734       47,065  
       
Long-term debt   182,681       189,861  
Deferred tax liabilities, net   8,648       8,641  
Other non-current liabilities   3,534       3,697  
       
Commitments, contingencies and regulatory matters      
       
Deficit:      
Common stock ($0.01 par value; 250,000 shares authorized, 11,432 issued and outstanding as of September 30, 2026; 11,021 issued and 10,994 outstanding as of December 31, 2025)   114       110  
Additional paid-in capital   259,542       257,359  
Accumulated deficit   (370,299 )     (363,735 )
Treasury stock, at cost (27 shares as of December 31, 2025)   —       (3,948 )
Altisource deficit   (110,643 )     (110,214 )
       
Non-controlling interests   759       751  
Total deficit   (109,884 )     (109,463 )
       
Total liabilities and deficit $ 136,713     $ 139,801  

   
ALTISOURCE PORTFOLIO SOLUTIONS S.A.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
   
  Nine months ended
September 30,
    2026       2025  
       
Cash flows from operating activities:      
Net (loss) income $ (2,445 )   $ 9,062  
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:      
Depreciation and amortization   202       443  
Amortization of right-of-use assets under operating leases   885       914  
Amortization of intangible assets   4,215       3,810  
Share-based compensation expense   3,331       3,066  
Bad debt expense   332       125  
Amortization of debt premium   (3,572 )     (2,893 )
Amortization of debt discount   318       815  
Amortization of debt issuance costs   171       501  
Gain on early extinguishment of debt   (1,008 )     —  
Deferred income taxes   7       91  
Changes in operating assets and liabilities:      
Accounts receivable   (9,018 )     (2,494 )
Prepaid expenses and other current assets   3,576       (1,110 )
Other assets   185       2,044  
Accounts payable and accrued expenses   6,701       (1,482 )
Current and non-current operating lease liabilities   (922 )     (952 )
Other current and non-current liabilities   (1,653 )     (16,500 )
Net cash provided by (used in) operating activities   1,305       (4,560 )
       
Cash flows from investing activities:      
Additions to premises and equipment   (939 )     (49 )
Other investing activities   —       (250 )
Net cash used in investing activities   (939 )     (299 )
       
Cash flows from financing activities:      
Proceeds from the Super Senior Facility   —       11,250  
Proceeds from exercise of cash settle stakeholder warrants   2       15  
Debt issuance costs   —       (1,741 )
Repayments and repurchases of long-term debt   (3,089 )     (613 )
Equity issuance costs   (265 )     (3,784 )
Purchase of fractional shares   —       (1 )
Distributions to non-controlling interests   (143 )     (146 )
Payments of tax withholding on vesting of restricted share units and restricted shares   (901 )     (343 )
Net cash (used in) provided by financing activities   (4,396 )     4,637  
       
Net decrease in cash, cash equivalents and restricted cash   (4,030 )     (222 )
Cash, cash equivalents and restricted cash at the beginning of the period   30,493       32,700  
       
Cash, cash equivalents and restricted cash at the end of the period $ 26,463     $ 32,478  
       
 
Nine months ended

September 30,
    2026       2025  
       
Supplemental cash flow information:      
Interest paid $ 9,457     $ 11,315  
Income taxes paid (refunded), net   179       (710 )
Acquisition of right-of-use assets with operating lease liabilities   380       121  
       
Non-cash investing and financing activities:      
Equity issued in exchange for debt reduction   —       45,370  
               

ALTISOURCE PORTFOLIO SOLUTIONS S.A.
NON-GAAP MEASURES
(in thousands, except per share data)
(unaudited)

Adjusted operating income, pretax loss attributable to Altisource, adjusted pretax income attributable to Altisource, adjusted net income attributable to Altisource, adjusted diluted earnings per share, Net cash provided by (used in) operating activities less additions to premises and equipment, Adjusted EBITDA, Business Segments Adjusted EBITDA and net debt, which are presented elsewhere in this earnings release, are non-GAAP measures used by management, existing shareholders, potential shareholders and other users of our financial information to measure Altisource’s performance and do not purport to be alternatives to income from operations, loss before income taxes and non-controlling interests, net (loss) income attributable to Altisource, diluted (loss) earnings per share, Net cash provided by (used in) operating activities and long-term debt, including current portion, as measures of Altisource’s performance. We believe these measures are useful to management, existing shareholders, potential shareholders and other users of our financial information in evaluating operating profitability and cash flow generation more on the basis of continuing cost and cash flows as they exclude amortization expense related to acquisitions that occurred in prior periods and non-cash share-based compensation, as well as the effect of more significant non-operational items from earnings, cash flows from operating activities and long-term debt net of cash on-hand. We believe these measures are also useful in evaluating the effectiveness of our operations and underlying business trends in a manner that is consistent with management’s evaluation of business performance. Furthermore, we believe the exclusion of more significant non-operational items enables comparability to prior period performance and trend analysis. Specifically, management uses adjusted net income attributable to Altisource to measure the on-going after tax performance of the Company because the measure adjusts for the after tax impact of more significant non-recurring items, amortization expense relating to prior acquisitions (some of which fluctuates with revenue from certain customers and some of which is amortized on a straight-line basis) and non-cash share-based compensation expense which can fluctuate based on vesting schedules, grant date timing and the value attributable to awards. We believe adjusted net income attributable to Altisource is useful to existing shareholders, potential shareholders and other users of our financial information because it provides an after-tax measure of Altisource’s on-going performance that enables these users to perform trend analysis using comparable data. Management uses adjusted diluted earnings per share to further evaluate adjusted net income attributable to Altisource while taking into account changes in the number of diluted shares over the comparable periods. We believe adjusted diluted earnings per share is useful to existing shareholders, potential shareholders and other users of our financial information because it also enables these users to evaluate adjusted net income attributable to Altisource on a per share basis. Management uses Adjusted EBITDA to measure the Company’s overall performance and Business Segments Adjusted EBITDA to measure the segments overall performance (with the adjustments discussed earlier with regard to adjusted net income attributable to Altisource) without regard to its capitalization (debt vs. equity) or its income taxes and to perform trend analysis of the Company’s performance over time. Our effective income tax rate can vary based on the jurisdictional mix of our income. Additionally, as the Company’s capital expenditures have significantly declined over time, it provides a measure for management to evaluate the Company’s performance without regard to prior capital expenditures. Management also uses Adjusted EBITDA as one of the measures in determining bonus compensation for certain employees. We believe Adjusted EBITDA and Business Segments Adjusted EBITDA are useful to existing shareholders, potential shareholders and other users of our financial information for the same reasons that management finds the measure useful. Management uses net debt in evaluating the amount of debt the Company has that is in excess of cash and cash equivalents. We believe net debt is useful to existing shareholders, potential shareholders and other users of our financial information for the same reasons management finds the measure useful.

Altisource operates in several countries, including Luxembourg, India, the United States and Uruguay. The Company has differing effective tax rates in each country and these rates may change from year to year. In determining the tax effects related to the adjustments in calculating adjusted net (loss) income attributable to Altisource and adjusted diluted earnings per share, we use the tax rate in the country in which the adjustment applies or, if the adjustment is recognized in more than one country, we separate the adjustment by country, apply the relevant tax rate for each country to the applicable adjustment, and then sum the result to arrive at the total adjustment, net of tax. In 2019, the Company recognized a full valuation allowance on its net deferred tax assets in Luxembourg. Accordingly, for 2026 and 2025, the Company has an effective tax rate of close to 0% in Luxembourg.

It is management’s intent to provide non-GAAP financial information to enhance the understanding of Altisource’s GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. Each non-GAAP financial measure is presented along with the corresponding GAAP measure so as not to imply that more emphasis should be placed on the non-GAAP measure. The non-GAAP financial information presented may be determined or calculated differently by other companies. The non-GAAP financial information should not be unduly relied upon.

Adjusted operating income is calculated by removing intangible asset amortization expense, share-based compensation expense, cost of cost savings initiatives and other and litigation matter from income from operations. Pretax loss attributable to Altisource is calculated by removing non-controlling interests from loss before income taxes and non-controlling interests. Adjusted pretax income attributable to Altisource is calculated by removing non-controlling interests, intangible asset amortization expense, share-based compensation expense, cost of cost savings initiatives and other, litigation matter and debt exchange transaction expenses from loss before income taxes and non-controlling interests. Adjusted net income attributable to Altisource is calculated by removing intangible asset amortization expense (net of tax), share-based compensation expense (net of tax), cost of cost savings initiatives and other (net of tax), debt exchange transaction expenses (net of tax), litigation matter (net of tax) and certain income tax related items from net (loss) income attributable to Altisource. Adjusted diluted earnings per share is calculated by dividing net (loss) income attributable to Altisource after removing intangible asset amortization expense (net of tax), share-based compensation expense (net of tax), cost of cost savings initiatives and other (net of tax), debt exchange transaction expenses (net of tax), litigation matter (net of tax) and certain income tax related items by the weighted average number of diluted shares. Net cash provided by (used in) operating activities less additions to premises and equipment is calculated by removing additions to premises and equipment from Net cash provided by (used in) operating activities. Adjusted EBITDA is calculated by removing the income tax provision, interest expense (net of interest income), depreciation and amortization, intangible asset amortization expense, share-based compensation expense, cost of cost savings initiatives and other, litigation settlement loss and debt exchange transaction expenses from net (loss) income attributable to Altisource. Business Segments Adjusted EBITDA is calculated by removing non-controlling interests, interest expense (net of interest income), depreciation and amortization, intangible asset amortization expense, share-based compensation expense, cost of cost savings initiatives and other, litigation matter and debt exchange transaction expenses from income before income taxes and non-controlling interests. Net debt is calculated as long-term debt, including current portion, minus cash and cash equivalents.

Reconciliations of the non-GAAP measures to the corresponding GAAP measures are as follows:

  Three months ended
September 30,
  Nine months ended
September 30,
    2026       2025       2026       2025  
               
Income from operations $ 764     $ 521     $ 3,620     $ 6,997  
               
Intangible asset amortization expense   1,368       1,270       4,215       3,810  
Share-based compensation expense   896       1,308       3,331       3,066  
Cost of cost savings initiatives and other   817       (436 )     1,359       (576 )
Litigation matter   —       —       (711 )     —  
Adjusted operating income $ 3,845     $ 2,663     $ 11,814     $ 13,297  
               
Loss before income taxes and non-controlling interests $ (993 )   $ (1,665 )   $ (680 )   $ (6,007 )
               
Non-controlling interests   —       (71 )     (151 )     (220 )
Pretax loss attributable to Altisource   (993 )     (1,736 )     (831 )     (6,227 )
Intangible asset amortization expense   1,368       1,270       4,215       3,810  
Share-based compensation expense   896       1,308       3,331       3,066  
Cost of cost savings initiatives and other   817       276       1,359       136  
Litigation matter   —       —       (711 )     —  
Debt exchange transaction expenses   —       194       —       3,646  
               
Adjusted pretax income attributable to Altisource $ 2,088     $ 1,312     $ 7,363     $ 4,431  
               
Net (loss) income attributable to Altisource $ (1,399 )   $ (2,396 )   $ (2,596 )   $ 8,842  
               
Income tax provision (benefit)   406       660       1,765       (15,069 )
Interest expense (net of interest income)   2,076       2,229       5,542       9,391  
Depreciation and amortization   88       80       202       443  
Intangible asset amortization expense   1,368       1,270       4,215       3,810  
Share-based compensation expense   896       1,308       3,331       3,066  
Cost of cost savings initiatives and other   817       276       1,359       136  
Litigation matter   —       —       (711 )     —  
Debt exchange transaction expenses   —       194       —       3,646  
               
Adjusted EBITDA $ 4,252     $ 3,621     $ 13,107     $ 14,265  
               
Business Segments:              
Income before income taxes and non-controlling interests $ 9,316     $ 8,616     $ 31,097     $ 31,296  
               
Non-controlling interests   —       (71 )     (151 )     (220 )
Depreciation and amortization   50       53       145       207  
Intangible asset amortization expense   1,368       1,270       4,215       3,810  
Share-based compensation expense   328       242       689       157  
Cost of cost savings initiatives and other   271       732       338       863  
Litigation matter   —       —       (711 )     —  
Interest expense (net of interest income)   9       51       23       97  
               
Business Segments Adjusted EBITDA $ 11,342     $ 10,893     $ 35,645     $ 36,210  
               
Corporate and Others:              
Loss before income taxes and non-controlling interests $ (10,309 )   $ (10,281 )   $ (31,777 )   $ (37,303 )
               
Depreciation and amortization   38       27       57       236  
Share-based compensation expense   568       1,066       2,642       2,909  
Cost of cost savings initiatives and other   546       (456 )     1,021       (727 )
Debt exchange transaction expenses   —       194       —       3,646  
Interest expense (net of interest income)   2,067       2,178       5,519       9,294  
               
Corporate and Others Adjusted EBITDA $ (7,090 )   $ (7,272 )   $ (22,538 )   $ (21,945 )
               
Net (loss) income attributable to Altisource $ (1,399 )   $ (2,396 )   $ (2,596 )   $ 8,842  
               
Intangible asset amortization expense, net of tax   1,329       1,270       4,109       3,810  
Share-based compensation expense, net of tax   797       1,207       3,063       2,862  
Cost of cost savings initiatives and other, net of tax   651       281       1,034       182  
Litigation matter, net of tax   9       —       (547 )     —  
Debt exchange transaction expenses, net of tax   —       194       —       3,646  
Certain income tax related items   133       536       583       (16,227 )
               
Adjusted net income attributable to Altisource $ 1,520     $ 1,092     $ 5,646     $ 3,115  
               
Diluted (loss) earnings per share $ (0.12 )   $ (0.22 )   $ (0.23 )   $ 0.81  
Impact of using diluted share count instead of basic share count for loss per share   —       —       0.01       —  
Intangible asset amortization expense, net of tax, per diluted share   0.11       0.12       0.35       0.35  
Share-based compensation expense, net of tax, per diluted share   0.07       0.11       0.26       0.26  
Cost of cost savings initiatives and other, net of tax, per diluted share   0.05       0.02       0.09       0.02  
Litigation matter, net of tax, per diluted share   —       —       (0.05 )     —  
Debt exchange transaction expenses, per diluted share   —       0.02       —       0.33  
Certain income tax related items, per diluted share   0.01       0.05       0.05       (1.49 )
               
Adjusted diluted earnings per share $ 0.13     $ 0.10     $ 0.48     $ 0.29  
               
Calculation of the per share impact of intangible asset amortization expense, net of tax              
Intangible asset amortization expense $ 1,368     $ 1,270     $ 4,215     $ 3,810  
Tax benefit from intangible asset amortization   (39 )     —       (106 )     —  
Intangible asset amortization expense, net of tax   1,329       1,270       4,109       3,810  
Diluted share count   11,882       10,988       11,742       10,890  
Intangible asset amortization expense, net of tax, per diluted share $ 0.11     $ 0.12     $ 0.35     $ 0.35  
               
Calculation of the per share impact of share-based compensation expense, net of tax              
Share-based compensation expense $ 896     $ 1,308     $ 3,331     $ 3,066  
Tax (benefit) provision from share-based compensation expense   (99 )     38       (268 )     (103 )
Share-based compensation expense, net of tax   797       1,207       3,063       2,862  
Diluted share count   11,882       10,988       11,742       10,890  
               
Share-based compensation expense, net of tax, per diluted share $ 0.07     $ 0.11     $ 0.26     $ 0.26  
               
Calculation of the impact of Litigation matter, net of tax              
Litigation matter $ —     $ —     $ (711 )   $ —  
Tax provision from Litigation matter   9       —       164       —  
Litigation matter, net of tax   9       —       (547 )     —  
Diluted share count   11,882       10,988       11,742       10,890  
               
Litigation matter, net of tax per diluted share $ —     $ —     $ (0.05 )   $ —  
               
Calculation of the impact of debt exchange transaction expenses, net of tax              
Debt exchange transaction expenses $ —     $ 194     $ —     $ 3,646  
Tax benefit from debt exchange transaction expenses   —       —       —       —  
Debt exchange transaction expenses, net of tax   —       194       —       3,646  
Diluted share count   11,882       10,988       11,742       10,890  
               
Debt exchange transaction expenses, net of tax per diluted share $ —     $ 0.02     $ —     $ 0.33  
               
Calculation of the per share impact of cost of cost savings initiatives and other, net of tax              
Cost of cost savings initiatives and other $ 817     $ 276     $ 1,359     $ 136  
Tax (benefit) provision from cost of cost savings initiatives and other   (166 )     27       (325 )     41  
Cost of cost savings initiatives and other, net of tax   651       281       1,034       182  
Diluted share count   11,882       10,988       11,742       10,890  
               
Cost of cost savings initiatives and other, net of tax, per diluted share $ 0.05     $ 0.02     $ 0.09     $ 0.02  
               
Calculation of the per share impact of certain income tax related items resulting from:              
Foreign income tax reserves / other $ —     $ (17,156 )   $ —     $ (16,763 )
Certain income tax related items   133       536       583       (16,227 )
Diluted share count   11,882       10,988       11,742       10,890  
               
Certain income tax related items, per diluted share $ 0.01     $ 0.05     $ 0.05     $ (1.49 )
               
Net cash provided by (used in) operating activities $ 3,482     $ 718     $ 1,305     $ (4,560 )
Less: additions to premises and equipment   (570 )     (21 )     (939 )     (49 )
               
Net cash provided by (used in) operating activities less additions to premises and equipment $ 2,912     $ 697     $ 366     $ (4,609 )

  September 30, 2026
   
Senior secured term loans $ 155,506  
Super senior term loan   12,297  
Less: Cash and cash equivalents   (25,055 )
   
Net debt $ 142,748  

Note: Amounts may not add to the total due to rounding.

 
FOR FURTHER INFORMATION CONTACT:
 
Michelle D. Esterman
Chief Financial Officer
T: (770) 612-7007
E: Michelle.Esterman@altisource.com

MitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation

Ness Ziona, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) — Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) recently announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has completed an initial computational screening stage under its drug-discovery initiative with Boltz, PBC (“Boltz”), an AI research lab focused on biomolecular foundation models and drug-discovery workflows. MitoCareX believes the preliminary computational predictions generated in this stage are encouraging and warrant further computational analysis and experimental validation.

Completion of this stage moves the initiative, announced in June 2026, from launch to an initial assessment of screening predictions. The predictions have not been experimentally validated and serve only as a starting point for evaluating potential follow-up research within MitoCareX’s small-molecule discovery programs.

The initiative combines MitoCareX’s proprietary drug-discovery capabilities with Boltz’s AI models to identify potential small-molecule starting points for selected discovery programs. MitoCareX retains control over its discovery programs and any small-molecule candidates it advances through the initiative.

Further scientific assessment and validation will determine whether the preliminary predictions support advancing any program. No assurance can be given that any compound identified through the initiative will be advanced into preclinical or clinical development.

About MitoCareX Bio Ltd.

MitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc., is advancing a focused drug-discovery platform designed to translate multidisciplinary scientific capabilities into potential therapeutic candidates. By integrating biology, chemistry and computationally enabled research, MitoCareX supports ongoing research activities directed toward candidate identification and development within its drug-discovery efforts. https://mitocarexbio.com/

About Nexentis Technologies Inc.

Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd., a drug-discovery company. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

For additional details, please visit https://nexentistech.com/

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “could,” “potential” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the significance of the preliminary computational predictions from the initial screening stage under MitoCareX’s drug-discovery initiative with Boltz; the potential for further computational analysis, experimental investigation and validation of such predictions; the assessment of next research steps and follow-up research opportunities within MitoCareX’s small-molecule discovery programs; the potential identification and advancement of small-molecule starting points or candidates; and the potential contribution of the initiative to MitoCareX’s broader discovery strategy. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, market and other conditions; our history of losses, our need for additional capital to fund our operations and our potential inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the risk that computational or AI-generated predictions may not be confirmed by experimental testing or may not identify viable candidates; our dependence on third-party collaborators, including Boltz, and their technologies; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates, including our renewable energy investments; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of the Nasdaq Capital Market; and the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026, and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com

SKOKIE, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) — LanzaTech Global, Inc. (NASDAQ: LNZA) (“LanzaTech” or the “Company”), a carbon management solutions company, today announced that it will issue its third quarter 2026 financial results before financial markets in the United States open on Monday, November 16, 2026. A conference call will be held that same day at 8:30 a.m. Eastern Time.

The conference call may be accessed via a live webcast on a listen-only basis through the Events & Presentations section of LanzaTech’s Investor Relations website, ir.lanzatech.com. An archive of the webcast will be available for twelve months.

To attend the live conference call via telephone, domestic callers can access by dialing 1-833-419-0865 and international callers by dialing 1-785-838-9333 using the conference identification code LANZA.

A replay of the conference call will be available shortly after the call ends and can be accessed by domestic callers by dialing 1-844-512-2921 and by international callers by dialing 1-412-317-6671 and entering the access identification code 11162824. The replay will be available until 11:59 p.m. Eastern Time on November 30, 2026.

About LanzaTech

LanzaTech (NASDAQ: LNZA) is a leader in carbon management, using its proprietary gas-fermentation platform to transform waste carbon into valuable products. Through global partnerships, LanzaTech enables the production of feedstocks for high-value markets including SAF and chemicals. Headquartered in the U.S., the company provides technology and commercial pathways that strengthen industrial resilience and unlock new economic value from carbon.

Investor Relations Contact:
LNZA@alpha-ir.com

Public Relations/Media Contact:
Freya Burton
freya@lanzatech.com

LAS VEGAS, Oct. 29, 2026 (GLOBE NEWSWIRE) — TRANSUITE.ORG INC. (OTCQB: TRSO) (“TRSO” or the “Company”) is advancing commercialization of AI and digital-payment applications across payment transactions, enterprise technology services and intelligent terminals to unlock long-term earning potential. SolanAI Global Limited, the Company’s controlled subsidiary, executes the digital-payment strategy. Its AI and IoT initiatives include cloud operations, data management and enterprise applications to enhance service capabilities and delivery efficiency.

On September 2, 2026, TRSO signed a Letter of Intent to acquire a 51% equity interest in Zhongke Haichuang (Fujian) Technology Co., Ltd. (“ZKHC”). The Company plans to complete the acquisition by the end of 2026. As a core independent software and comprehensive value-added service provider for Douyin Pay, ZKHC maintains proprietary technology and a national service team, offering AI‑SaaS platforms, merchant management, intelligent marketing, aggregated collection and cross-border payment solutions. SolanAI will carry out phased technology integration and rollout.

Expanding paid customers on shared platforms may dilute fixed R&D and operating costs, while AI automation reduces routine service expenses. Subject to successful closing of the acquisition, ZKHC plans to open direct operation centers in more than 20 provinces and cities in China, gradually build several thousand franchise marketing teams and target coverage of millions of merchants. ZKHC has set non-binding 2026 internal targets for SolanAI of approximately $60 million in revenue and $10 million in net profit. These internal planning targets are not earnings guidance, financial guarantees or audited projections, and the Company cannot guarantee they will be achieved.

For the six months ending June 30, 2026, SolanAI generated no revenue and reported a segment loss of $257,497. Meeting these targets requires large-scale expansion; first-half results do not guarantee success. If products launch smoothly, merchants expand steadily and payment activity normalizes, the business may generate new earnings for TRSO.

TRANSUITE.ORG INC. is a Nevada technology holding company listed under ticker TRSO. Near-term focus includes Electric two-wheeler charging infrastructure; longer-term priorities cover AI, digital payments and Web3.

Forward-Looking Statements: Commercialization and operating targets are forward-looking, subject to financing, execution, customer adoption, cost and regulatory risks detailed in the Company’s SEC filings. Actual results may differ materially. The Company does not reaffirm prior targets and assumes no obligation to update these statements.

Investor Contact: ir@transuite.org | +1 (775) 295-4295 | www.transuite.org

Industrial edge networking stack enables real-time communications for AI automation, robotics and Industry 4.0 applications

CHANDLER, Ariz., Oct. 29, 2026 (GLOBE NEWSWIRE) — As industrial systems evolve to support AI-enabled automation, robotics and intelligent edge computing, developers need to deliver deterministic, real-time networking while minimizing power consumption, maintaining security and reducing system complexity. To address these challenges, Microchip Technology (Nasdaq: MCHP) has expanded its industrial edge networking solution stack with EtherCAT® and Time-Sensitive Networking (TSN) capabilities on PolarFire® devices. Beckhoff® Automation GmbH EtherCAT IP is compatible with both PolarFire® FPGA and SoC devices and Microchip TSN IP is supported on PolarFire FPGA SoCs. These enhancements expand Microchip’s growing portfolio of FPGA solution stacks which combine hardware, IP, development tools and reference designs to accelerate development across industrial networking, AI, machine learning and security-focused applications.

“Industrial networks are becoming more intelligent, distributed and data driven as AI moves closer to the edge,” said Shakeel Peera, vice president of Microchip’s FPGA business unit. “By adding EtherCAT and TSN capabilities to our power-efficient PolarFire platform, we’re providing developers with the deterministic networking technologies needed to build highly responsive, scalable systems for industrial and embedded networking applications.”

Beckhoff EtherCAT IP supports EtherCAT connectivity at 10/100/1000 Mbps and Microchip’s TSN solution enables deterministic 1 Gbps Ethernet using IEEE 802.1 Time-Sensitive Networking standards. Together, these technologies help developers build scalable industrial networks with predictable communication performance and interoperability across connected devices.

Built on power-efficient PolarFire FPGAs and SoCs, the industrial edge networking solution stack delivers real-time processing with high reliability and energy efficiency. PolarFire devices feature a secure, non-volatile architecture that enables instant-on operation and supports integrated security features such as secure boot and anti-tamper protection. The flexible FPGA fabric enables EtherCAT and TSN integration while supporting scalable customization for evolving industrial network architectures.

Target applications include motion control, industrial robotics, embedded vision, factory automation, autonomous mobile robots, automotive systems, smart infrastructure and aerospace and defense platforms. PolarFire FPGA and SoC industrial networking solutions are supported by Microchip’s Libero® SoC design suite, IP cores and reference designs, as well as the Dual-Port Gigabit Ethernet FMC card (ETH-DC-DUALGBE) and PolarFire® SoC Video Kit (MPFS250-VIDEO-KIT) for rapid evaluation and prototyping. Visit the website to learn more about Microchip’s full portfolio of FPGA devices.

Resources
High-res images available through Flickr or editorial contact (feel free to publish):

About Microchip Technology:
Microchip Technology Inc. is a broadline supplier of semiconductors committed to making innovative design easier through total system solutions that address critical challenges at the intersection of emerging technologies and durable end markets. Its easy-to-use development tools and comprehensive product portfolio supports customers throughout the design process, from concept to completion. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support and delivers solutions across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. For more information, visit the Microchip website at www.microchip.com.

Note: The Microchip name and logo, the Microchip logo, Libero and PolarFire are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. All other trademarks mentioned herein are the property of their respective companies.

Editorial Contact:
Amber Liptai
480-792-5047
amber.liptai@microchip.com

CHICAGO, Oct. 29, 2026 (GLOBE NEWSWIRE) — CCC Intelligent Solutions Holdings Inc. (“CCC” or the “Company”) (NASDAQ: CCC), a leading SaaS and AI platform provider for the multi-trillion-dollar insurance economy, today announced its financial results for the three months ended September 30, 2026.

“CCC delivered strong third quarter results, with revenue growth of 10% and adjusted EBITDA margin of approximately 44%. Our performance reflects the durability of our business, the trust customers place in us, and the increasing role our platform plays in helping participants across the insurance economy operate more efficiently and achieve better outcomes,” said Githesh Ramamurthy, Chairman & CEO of CCC.

“The pending transaction with GTCR and Elliott marks an exciting next chapter for CCC and our customers,” continued Ramamurthy. “Together, we expect to accelerate the AI and agentic capabilities our customers want from us, expand the network at the center of our platform, and make long-term investments in innovation that help customers navigate growing complexity across the claims lifecycle. We believe this positions CCC to deliver even greater value to the insurance economy in the years ahead.”

Third Quarter 2026 Financial Highlights

Revenue

  •   Total revenue was $294.1 million for the third quarter of 2026, an increase of 10.1% from $267.1 million for the third quarter of 2025.


Profitability

  •   GAAP gross profit was $218.0 million, representing a gross margin of 74%, for the third quarter of 2026, compared with $193.0 million, representing a gross margin of 72%, for the third quarter of 2025. Adjusted gross profit was $224.6 million, representing an adjusted gross profit margin of 76%, for the third quarter of 2026, compared with $199.5 million, representing an adjusted gross profit margin of 78%, for the third quarter of 2025.
       
  •   GAAP operating income was $57.4 million for the third quarter of 2026, compared with GAAP operating income of $30.0 million for the third quarter of 2025. Adjusted operating income was $115.7 million for the third quarter of 2026, compared with adjusted operating income of $93.0 million for the third quarter of 2025.
       
  •   GAAP net income was $30.2 million for the third quarter of 2026, compared with GAAP net loss of $2.0 million for the third quarter of 2025. Adjusted net income was $75.1 million for the third quarter of 2026, compared with $59.4 million for the third quarter of 2025.
       
  •   Adjusted EBITDA was $130.5 million for the third quarter of 2026, up 18.5% compared with adjusted EBITDA of $110.1 million for the third quarter of 2025.


Liquidity

  •   CCC had $202.9 million in cash and cash equivalents and $1.28 billion of total debt as of September 30, 2026. The Company generated $100.4 million in cash from operating activities and had free cash flow of $82.5 million for the third quarter of 2026, compared with $94.8 million in cash generated from operating activities and free cash flow of $78.6 million for the third quarter of 2025.


3
rd Quarter and Recent Business Highlights

  • GTCR and Elliott to acquire CCC. On October 15, 2026, CCC announced a definitive agreement to be acquired by a consortium of private investment firms led by GTCR and including Elliott Investment Management in an all-cash transaction in which shareholders will receive $7.75 per share, representing an enterprise value of approximately $6.1 billion. Subject to regulatory and stockholder approvals and other customary closing conditions, the proposed transaction is expected to close in the first quarter of 2027. Following the close, CCC will become a privately held company.
  • Insurers expand AI adoption across core claims workflows. CCC’s AI-related revenue reached approximately $130 million in annualized run-rate in the third quarter of 2026, representing growth of 40% year over year and increasing from an annualized run rate of approximately $120 million in the second quarter of 2026. This growth reflects a continuing shift in customer behavior from AI experimentation to AI deployment at scale.
  • Leading insurer is largest to adopt Medhub for Auto Casualty. During the third quarter of 2026, a top-five insurer (based on 2025 direct premium written) became the largest insurer to adopt CCC’s Medhub for Auto Casualty, which uses AI to extract critical insights from complex medical records and help claims professionals make faster, more informed decisions grounded in auditable claim data. The deployment marks the largest application of EvolutionIQ’s technology within the P&C auto market and demonstrates customers’ willingness to adopt adjacent workflows from CCC, underscoring the substantial growth opportunity beyond the traditional APD business.

Business Outlook and Conference Call Information

In light of the proposed transaction, the Company is suspending its practice of providing guidance and will not be hosting a conference call or webcast to discuss the Company’s financial results.

About CCC Intelligent Solutions

CCC Intelligent Solutions Inc. (CCC), a subsidiary of CCC Intelligent Solutions Holdings Inc. (NASDAQ: CCC), is a leading SaaS and AI platform provider powering the multi-trillion-dollar insurance and repair economy. CCC connects more than 35,000 businesses, including insurers, repairers, automakers and parts suppliers, through the workflows where claims and repair decisions are made every day. With AI built into those workflows for over a decade and informed by more than 40 years of industry data, CCC helps customers manage growing complexity and move work forward with confidence. Through purposeful innovation and the strength of its network, CCC helps keep people’s lives moving forward when it matters most. Learn more about CCC at www.cccis.com.

Forward Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, future events, goals, plans and projections regarding the Company’s financial position, results of operations, market position, product development and business strategy. Such differences may be material. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive transaction documents concerning the proposed transaction, including circumstances requiring payment of a termination fee pursuant to the definitive transaction documents; the failure to obtain stockholder approval of the proposed transaction, or the failure to satisfy other conditions to completion, of the proposed transaction; the risk that regulatory approvals required for the proposed transaction may not be obtained in a timely manner or at all, or may be obtained subject to conditions that are not anticipated; the failure to satisfy the other conditions to the consummation of the proposed transaction on a timely basis or at all; risks related to the disruption of management’s attention from the Company’s ongoing business operations due to the proposed transaction; the effect of the announcement or pendency of the proposed transaction on the Company’s business relationships, operating results and business generally; the risk the proposed transaction may not be completed in the time frame expected by the parties or at all; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of the Company’s common stock; the risk of any litigation related to the proposed transaction; the possibility that competing offers will be made; the risk that certain restrictions during the pendency of the proposed transaction may impact the Company’s ability to pursue certain business opportunities or strategic transactions; our revenues, the concentration of our customers and the ability to retain our current customers; our ability to negotiate with our customers on favorable terms; our ability to maintain and grow our brand and reputation cost-effectively; the execution of our growth strategy; the impact of factors outside our control including public health outbreaks, natural catastrophes, war and terrorism; our projected financial information, growth rate and market opportunity; the health of our industry, claim volumes, and market conditions; changes in the insurance and automotive collision industries, including the adoption of new technologies; global economic conditions and geopolitical events; competition in our market and our ability to retain and grow market share; our ability to develop, introduce and market new enhanced versions of our solutions; our sales and implementation cycles; the ability of our research and development efforts to create significant new revenue streams; changes in applicable laws or regulations; changes in international economic, political, social and governmental conditions and policies, including corruption risks in China and other countries; our reliance on third-party data, technology and intellectual property; our ability to protect our intellectual property; our ability to keep our data and information systems secure from data security breaches; changes in our customers’ or the public’s perceptions regarding the use of artificial intelligence; our ability to acquire or invest in companies or pursue business partnerships; our ability to raise financing in the future and improve our capital structure; our success in retaining or recruiting, or changes required in, our officers, key employees or directors; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our ability to expand or maintain our existing customer base; our ability to service our indebtedness; and other risks and uncertainties, including those included under the header “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2026, filed with the Securities and Exchange Commission (“SEC”), which can be obtained, without charge, at the SEC’s website (www.sec.gov), and in our other filings with the SEC. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Non-GAAP Financial Measures

This press release includes certain financial measures not presented in accordance with generally accepted accounting principles in the U.S. (“GAAP”), including, but not limited to, “adjusted EBITDA,” “adjusted EBITDA margin,” “adjusted net income,” “adjusted operating income,” “adjusted gross profit,” “adjusted gross profit margin,” “adjusted operating expenses,” and “free cash flow” in each case presented on a non-GAAP basis, and certain ratios and other metrics derived therefrom. These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing the Company’s financial results. Therefore, these measures should not be considered in isolation or as an alternative to other measures of profitability, liquidity or performance under GAAP. You should be aware that the Company’s calculation of these non-GAAP measures may not be comparable to similarly-titled measures used by other companies.

The Company believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. Please refer to the reconciliations of these measures below to what the Company believes are the most directly comparable measures evaluated in accordance with GAAP.

Additional Information and Where to Find It

This communication is being made in respect of the proposed acquisition of the Company by affiliates of GTCR or Elliott and related transactions (collectively, the “proposed transaction”). In accordance with the definitive transaction documents, a meeting of the stockholders of the Company will be announced as promptly as practicable to seek the Company’s stockholder approval in connection with the proposed transaction. The Company intends to file relevant materials with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. The definitive proxy statement (the “Proxy Statement”) will be mailed to the Company’s stockholders. This communication is not a substitute for the Proxy Statement or any other document that may be filed by the Company with the SEC or sent to its stockholders in connection with the proposed transaction. BEFORE MAKING ANY DECISION, THE COMPANY’S STOCKHOLDERS AND INVESTORS ARE URGED TO CAREFULLY READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE INTO THE PROXY STATEMENT AS, IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, GTCR or Elliott AND THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain a free copy of the Proxy Statement (when available) as well as other documents filed by the Company with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company’s website at https://ir.cccis.com or by contacting the Company’s investor relations department at IR@cccis.com.

Participants in the Solicitation

The Company and its directors and executive officers may be considered participants in the solicitation of proxies from the Company’s stockholders in connection with the proposed transaction. Information about the directors and executive officers of the Company, including a description of their beneficial ownership of the Company’s securities, is set forth in the Company’s proxy statement for its 2026 annual meeting of stockholders, which was filed with the SEC on April 7, 2026 (the “Annual Meeting Proxy Statement”). To the extent the holdings of the Company’s securities by its directors or executive officers have changed since the amounts set forth in the Annual Meeting Proxy Statement, such changes have been or will be reflected on Forms 3, 4 and 5 filed with the SEC. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, in the proposed transaction will be contained in the Proxy Statement and in other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. You may obtain these documents (when they become available) as described above.

Investor Contact:
Bill Warmington
VP, Investor Relations, CCC Intelligent Solutions Inc.
312-229-2355
IR@cccis.com

Media Contact:
Michelle Hellyar
Senior Director, Public Relations, CCC Intelligent Solutions Inc.
mhellyar@cccis.com

 
CCC INTELLIGENT SOLUTIONS HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
    September 30,   December 31,
      2026       2025  
    (Unaudited)    
ASSETS        
CURRENT ASSETS:        
Cash and cash equivalents   $ 202,926     $ 111,192  
Accounts receivable—Net of allowances of $4,044 and $3,773 as of September 30, 2026 and December 31, 2025, respectively     142,078       137,056  
Income taxes receivable     24,933       33,274  
Deferred contract costs     22,897       24,923  
Other current assets     33,679       28,653  
Total current assets     426,513       335,098  
SOFTWARE, EQUIPMENT, AND PROPERTY—Net     173,171       166,796  
OPERATING LEASE ASSETS     34,258       36,047  
INTANGIBLE ASSETS—Net     942,018       1,010,658  
GOODWILL     1,955,551       1,955,551  
DEFERRED FINANCING FEES, REVOLVER—Net     1,092       1,368  
DEFERRED CONTRACT COSTS     20,824       22,479  
EQUITY METHOD INVESTMENT     10,228       10,228  
OTHER ASSETS     38,406       35,207  
TOTAL   $ 3,602,061     $ 3,573,432  
LIABILITIES AND STOCKHOLDERS’ EQUITY        
CURRENT LIABILITIES:        
Accounts payable   $ 24,245     $ 30,954  
Accrued expenses     78,976       80,897  
Current portion of long-term debt     13,033       13,033  
Current portion of long-term licensing agreement—Net     3,632       3,466  
Operating lease liabilities     6,072       7,785  
Deferred revenues     54,917       72,793  
Note payable to minority investor     27,562       25,197  
Total current liabilities     208,437       234,125  
LONG-TERM DEBT—Net     1,256,563       1,264,941  
DEFERRED INCOME TAXES—Net     217,194       199,311  
LONG-TERM LICENSING AGREEMENT—Net     18,223       20,968  
OPERATING LEASE LIABILITIES     50,014       51,467  
OTHER LIABILITIES     9,745       15,610  
Total liabilities     1,760,176       1,786,422  
COMMITMENTS AND CONTINGENCIES (Notes 19 and 20)        
STOCKHOLDERS’ EQUITY:        
Preferred stock—$0.0001 par; 100,000,000 shares authorized; no shares issued or outstanding     —       —  
Common stock—$0.0001 par; 5,000,000,000 shares authorized; 590,525,042 and
605,449,050 shares issued and outstanding as of September 30, 2026 and December 31, 2025,
respectively
    59       60  
Additional paid-in capital     3,571,841       3,483,031  
Accumulated deficit     (1,729,118 )     (1,695,057 )
Accumulated other comprehensive loss     (897 )     (1,024 )
Total stockholders’ equity     1,841,885       1,787,010  
TOTAL   $ 3,602,061     $ 3,573,432  

 
CCC INTELLIGENT SOLUTIONS HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(In thousands, except share and per share data)
(Unaudited)
    For the Three Months Ended   For the Nine Months Ended
    September 30,   September 30,
      2026       2025       2026       2025  
REVENUES   $ 294,093     $ 267,120     $ 861,298     $ 779,136  
COST OF REVENUES                
Cost of revenues, exclusive of amortization of acquired technologies     71,719       69,779       210,671       194,050  
Amortization of acquired technologies     4,368       4,368       13,105       13,105  
Total cost of revenues     76,087       74,147       223,776       207,155  
GROSS PROFIT     218,006       192,973       637,522       571,981  
OPERATING EXPENSES:                
Research and development     53,042       52,947       158,556       174,639  
Selling and marketing     38,017       44,208       120,934       135,980  
General and administrative     51,049       47,332       148,660       162,080  
Amortization of intangible assets     18,511       18,512       55,535       55,536  
Total operating expenses     160,619       162,999       483,685       528,235  
OPERATING INCOME     57,387       29,974       153,837       43,746  
INTEREST EXPENSE     (20,900 )     (18,103 )     (61,559 )     (52,866 )
INTEREST INCOME     1,365       1,065       3,050       4,233  
OTHER INCOME (EXPENSE)—NET     2,082       466       8,615       (6,688 )
PRETAX INCOME (LOSS)     39,934       13,402       103,943       (11,575 )
INCOME TAX (PROVISION) BENEFIT     (9,703 )     (15,373 )     (37,508 )     5,143  
NET INCOME (LOSS) INCLUDING NON-CONTROLLING
INTEREST
    30,231       (1,971 )     66,435       (6,432 )
LESS: ACCRETION OF REDEEMABLE NON-CONTROLLING INTEREST     —       —       —       (1,276 )
NET INCOME (LOSS) ATTRIBUTABLE TO CCC INTELLIGENT
SOLUTIONS HOLDINGS INC. COMMON STOCKHOLDERS
  $ 30,231     $ (1,971 )   $ 66,435     $ (7,708 )
Net income (loss) per share attributable to common stockholders:                
Basic   $ 0.05     $ (0.00 )   $ 0.11     $ (0.01 )
Diluted   $ 0.05     $ (0.00 )   $ 0.11     $ (0.01 )
Weighted-average shares used in computing net income (loss) per share
attributable to common stockholders:
               
Basic     575,679,641       631,440,015       578,837,408       635,263,670  
Diluted     593,430,988       631,440,015       595,291,220       635,263,670  
COMPREHENSIVE INCOME (LOSS):                
Net income (loss) including non-controlling interest     30,231       (1,971 )     66,435       (6,432 )
Other comprehensive income—Foreign currency translation
adjustment
    33       83       127       121  
COMPREHENSIVE INCOME (LOSS) INCLUDING
NON-CONTROLLING INTEREST
    30,264       (1,888 )     66,562       (6,311 )
Less: accretion of redeemable non-controlling interest     —       —       —       (1,276 )
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO CCC
INTELLIGENT SOLUTIONS HOLDINGS INC. COMMON
STOCKHOLDERS
  $ 30,264     $ (1,888 )   $ 66,562     $ (7,587 )

 
CCC INTELLIGENT SOLUTIONS HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
    For the Nine Months Ended
    September 30,
      2026       2025  
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net income (loss)   $ 66,435     $ (6,432 )
Adjustments to reconcile net income (loss) to net cash provided by operating activities:        
Depreciation and amortization of software, equipment, and property     42,120       44,376  
Amortization of intangible assets     68,640       68,641  
Deferred income taxes     17,883       (1,208 )
Stock-based compensation     93,794       146,216  
Amortization of deferred financing fees     1,562       1,405  
Amortization of discount on debt     110       117  
Change in fair value of derivative instruments     (10,019 )     8,441  
Noncash interest expense     2,365       1,491  
Changes in:        
Accounts receivable—Net     (5,051 )     (33,743 )
Deferred contract costs     2,026       (566 )
Other current assets     (2,422 )     (2,770 )
Deferred contract costs—Non-current     1,655       (1,902 )
Other assets     (3,199 )     139  
Operating lease assets     1,789       1,855  
Income taxes     10,482       (30,733 )
Accounts payable     (6,707 )     3,813  
Accrued expenses     (364 )     (6,720 )
Operating lease liabilities     (3,166 )     (3,277 )
Deferred revenues     (17,875 )     10,073  
Other liabilities     (594 )     (2,901 )
Net cash provided by operating activities     259,464       196,315  
CASH FLOWS FROM INVESTING ACTIVITIES:        
Purchases of software, equipment, and property     (52,966 )     (46,684 )
Acquisition of EvolutionIQ, Inc., net of cash acquired     —       (410,412 )
Net cash used in investing activities     (52,966 )     (457,096 )
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from exercise of stock options     9,314       3,603  
Proceeds from employee stock purchase plan     4,338       5,044  
Payments for employee taxes withheld upon vesting of equity awards     (18,631 )     (48,262 )
Repurchase of common stock     (100,166 )     (212,485 )
Proceeds from issuance of long-term debt     —       225,000  
Payments of fees associated with the debt modification     —       (6,565 )
Principal payments on long-term debt     (9,774 )     (7,508 )
Net cash used in financing activities     (114,919 )     (41,173 )
NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS     155       112  
NET CHANGE IN CASH AND CASH EQUIVALENTS     91,734       (301,842 )
CASH AND CASH EQUIVALENTS:        
Beginning of period     111,192       398,983  
End of period   $ 202,926     $ 97,141  
NONCASH INVESTING AND FINANCING ACTIVITIES:        
Noncash purchases of software, equipment, and property   $ 2,633     $ —  
Stock issued related the acquisition of EvolutionIQ, Inc.   $ —     $ 250,441  
Issuance of promissory note to minority investor of redeemable preferred securities   $ —     $ 22,955  
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:        
Cash paid for interest   $ 57,637     $ 51,893  
Cash paid for income taxes—Net   $ 9,142     $ 26,199  

         
CCC INTELLIGENT SOLUTIONS HOLDINGS INC. AND SUBSIDIARIES
RECONCILIATION OF GROSS PROFIT TO ADJUSTED GROSS PROFIT
(In thousands, except profit margin percentage data)
(Unaudited)
         
    Three Months Ended September 30,   Nine Months Ended September 30,
         
(amounts in thousands, except percentages)     2026       2025       2026       2025  
Gross Profit   $ 218,006     $ 192,973     $ 637,522     $ 571,981  
Amortization of acquired technologies     4,368       4,368       13,105       13,105  
Stock-based compensation and related employer payroll tax     2,265       2,156       6,913       9,395  
Adjusted Gross Profit   $ 224,639     $ 199,497     $ 657,540     $ 594,481  
Gross Profit Margin     74 %     72 %     74 %     73 %
Adjusted Gross Profit Margin     76 %     75 %     76 %     76 %

         
CCC INTELLIGENT SOLUTIONS HOLDINGS INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP OPERATING EXPENSES TO ADJUSTED OPERATING EXPENSES
(In thousands)
(Unaudited) 
         
    Three Months Ended
September 30,
  Nine Months Ended
September 30,
(dollar amounts in thousands)     2026       2025       2026       2025  
Operating expenses   $ 160,619     $ 162,999     $ 483,685     $ 528,235  
Amortization of intangible assets     (18,511 )     (18,512 )     (55,535 )     (55,536 )
Stock-based compensation expense and related employer payroll tax     (29,493 )     (37,623 )     (90,446 )     (142,562 )
M&A and integration costs     (3,657 )     (234 )     (4,164 )     (8,200 )
Equity transaction costs, including secondary offerings     —       (177 )     —       (629 )
Litigation proceeds, net     —       —       —       3,665  
Debt refinancing costs     —       —       —       (3,119 )
Adjusted Operating Expenses   $ 108,958     $ 106,453     $ 333,540     $ 321,854  

         
CCC INTELLIGENT SOLUTIONS HOLDINGS INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP OPERATING INCOME TO ADJUSTED OPERATING INCOME
(In thousands)
(Unaudited) 
         
    Three Months Ended September 30,   Nine Months Ended September 30,
(dollar amounts in thousands)     2026     2025     2026     2025  
Operating income   $ 57,387   $ 29,974   $ 153,837   $ 43,746  
Amortization of intangible assets     18,511     18,512     55,535     55,536  
Amortization of acquired technologies—Cost of revenue     4,368     4,368     13,105     13,105  
Stock-based compensation expense and related employer payroll tax     31,758     39,779     97,359     151,957  
M&A and integration costs     3,657     234     4,164     8,200  
Equity transaction costs, including secondary offerings     —     177     —     629  
Litigation proceeds, net     —     —     —     (3,665 )
Debt refinancing costs     —     —     —     3,119  
Adjusted Operating Income   $ 115,681   $ 93,044   $ 324,000   $ 272,627  

         
CCC INTELLIGENT SOLUTIONS HOLDINGS INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA
(In thousands, except for EBITDA margin percentage data)
(Unaudited)
         
    Three Months Ended September 30,   Nine Months Ended September 30,
         
(dollar amounts in thousands)     2026       2025       2026       2025  
Net income (loss)   $ 30,231     $ (1,971 )   $ 66,435     $ (6,432 )
Interest expense     20,900       18,103       61,559       52,866  
Interest income     (1,365 )     (1,065 )     (3,050 )     (4,233 )
Income tax provision (benefit)     9,703       15,373       37,508       (5,143 )
Amortization of intangible assets     18,511       18,512       55,535       55,536  
Amortization of acquired technologies—Cost of revenue     4,368       4,368       13,105       13,105  
Depreciation and amortization of software, equipment and property     2,048       2,180       6,069       6,675  
Depreciation and amortization of software, equipment and property—Cost of revenue     12,763       14,823       36,051       37,701  
Stock-based compensation expense and related employer payroll tax     31,758       39,779       97,359       151,957  
M&A and integration costs     3,657       234       4,164       8,200  
Litigation proceeds, net     —       —       —       (3,665 )
Debt refinancing costs     —       —       —       3,119  
Equity transaction costs, including secondary offerings     —       177       —       629  
Change in fair value of derivative instruments     (2,514 )     60       (10,019 )     8,441  
Expense (Income) from derivative instruments     479       (453 )     1,501       (1,442 )
Adjusted EBITDA   $ 130,539     $ 110,120     $ 366,217     $ 317,314  
Adjusted EBITDA Margin     44 %     41 %     43 %     41 %

         
CCC INTELLIGENT SOLUTIONS HOLDINGS INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED NET INCOME
(In thousands, except share and per share data)
(Unaudited)
         
    Three Months Ended September 30,   Nine Months Ended September 30,
(dollar amounts in thousands)     2026       2025       2026       2025  
Net income (loss)   $ 30,231     $ (1,971 )   $ 66,435     $ (6,432 )
Amortization of intangible assets     18,511       18,512       55,535       55,536  
Amortization of acquired technologies—Cost of revenue     4,368       4,368       13,105       13,105  
Stock-based compensation expense and related employer payroll tax     31,758       39,779       97,359       151,957  
M&A and integration costs     3,657       234       4,164       8,200  
Litigation proceeds, net     —       —       —       (3,665 )
Debt refinancing costs     —       —       —       3,119  
Equity transaction costs, including secondary offerings     —       177       —       629  
Change in fair value of derivative instruments     (2,514 )     60       (10,019 )     8,441  
Tax effect of adjustments     (10,863 )     (1,730 )     (23,344 )     (58,124 )
Adjusted Net Income   $ 75,148     $ 59,429     $ 203,235     $ 172,766  
Adjusted Net Income Per Share attributable to common stockholders:                
Basic   $ 0.13     $ 0.09     $ 0.35     $ 0.27  
Diluted   $ 0.13     $ 0.09     $ 0.34     $ 0.26  
Weighted average shares outstanding:                
Basic     575,679,641       631,440,015       578,837,408       635,263,670  
Diluted     593,430,988       657,825,243       595,291,220       664,060,542  

         
CCC INTELLIGENT SOLUTIONS HOLDINGS INC. AND SUBSIDIARIES
RECONCILIATION OF NET CASH FLOW FROM OPERATING ACTIVITIES TO FREE CASH FLOW
(In thousands)
(Unaudited)
         
    Three Months Ended September 30,   Nine Months Ended September 30,
(dollar amounts in thousands)     2026       2025       2026       2025  
Net cash provided by operating activities   $ 100,429     $ 94,767     $ 259,464     $ 196,315  
Purchases of software, equipment, and property     (17,964 )     (16,135 )     (52,966 )     (46,684 )
Free Cash Flow   $ 82,465     $ 78,632     $ 206,498     $ 149,631  

SHANGHAI, Oct. 29, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the first patient dosing has been completed in a multi-center, randomized, controlled, and open-label phase 3 clinical study evaluating the efficacy and safety of the company’s product, recombinant humanized anti-PD-1/VEGF bispecific antibody (code: JS207), in combination with recombinant humanized anti-CTLA-4 monoclonal antibody (code: JS007) compared to toripalimab in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma (JS207-017-III-HCC Study, NCT07823348).

Liver cancer is a common malignant tumor of the digestive system worldwide, with hepatocellular carcinoma (HCC) being the main pathological type (accounting for approximately 90%). China bears an exceptionally heavy disease burden of liver cancer. According to statistics of GLOBOCAN 2024, there were approximately 354,100 new liver cancer cases and 303,800 liver cancer deaths in China in 2024, making it the second leading cause of cancer-related death after lung cancer. Due to its insidious onset, over 50% of patients are diagnosed at an intermediate or advanced stage.

Systemic therapy is an important treatment modality for intermediate and advanced liver cancer, which primarily includes molecular targeted drugs, immunotherapy and systemic chemotherapy. However, as the median overall survival of current first-line systemic therapies is less than 2 years, there remain substantial unmet clinical needs for patients with intermediate and advanced liver cancer.

In October 2026, the results of a phase 2 clinical study of JS207 in combination with JS007 for the first-line treatment of advanced HCC were presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract No.: #1693eP). The study results showed that the drug combination therapy exhibited robust anti-tumor activity. A total of 36 patients received treatment of JS207 in combination with JS007 (3 mg/kg Q6W for two cycles, and 1 mg/kg Q6W (i.e. recommended dose) thereafter). Among 34 efficacy-evaluable patients, the objective response rate (ORR) of combined treatment reached 44.1%, the disease control rate (DCR) reached 85.3%, the median progression-free survival (PFS) had not yet been reached, and the six-month PFS rate reached 67%. The drug combination therapy was well tolerated.

JS207-017-III-HCC study is a multi-center, randomized, controlled, open-label phase 3 clinical study. The study aims to evaluate the efficacy and safety of JS207 in combination with JS007 compared to toripalimab in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma. This study plans to enroll 560 subjects, and the primary endpoints are PFS and overall survival (OS).

About JS207

JS207 is a recombinant humanized anti-PD-1/VEGF bispecific antibody self-developed by Junshi Biosciences, mainly used for the treatment of advanced malignant tumors. JS207 can simultaneously bind to PD-1 and VEGFA with high affinity, effectively block the binding of PD-1 to PD-L1 and PD-L2, and inhibit the binding of VEGF to its receptor. JS207 has the efficacy properties of both immunotherapeutic drugs and anti-angiogenic drugs. Through the neutralization of VEGF, JS207 inhibits the proliferation of vascular endothelial cells, improves the tumor microenvironment and increases the infiltration of cytotoxic T lymphocytes in the tumor microenvironment, thereby achieving better anti-tumor activity.

JS207 is designed based on the high-affinity, clinically proven and differentiated anti-PD-1 drug toripalimab as the backbone. The anti-PD-1 moiety of JS207 adopts a Fab structure to maintain binding affinity to PD-1 and thereby attain better enrichment in the tumor microenvironment. The anti-VEGF moiety has a binding affinity for human vascular endothelial growth factor that is comparable to that of bevacizumab. In non-clinical in vitro cytological tests, compared with the combination of an anti-PD-1/PD-L1 monoclonal antibody and a VEGF monoclonal antibody, a bispecific antibody simultaneously targeting PD-1/PD-L1 and VEGF demonstrated significantly enhanced PD-1 antigen binding and internalization, and synergistic enhancement of the NFAT signaling pathway, thereby better activating immune cells in the tumor microenvironment.

About JS007

JS007 is a recombinant humanized anti-CTLA-4 monoclonal antibody injection self-developed by the Company, mainly used for the treatment of advanced malignant tumors. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is an important receptor for T cell surface modulates immune response. Studies have shown that JS007 is able to bind to CTLA-4 specifically and block the interaction between CTLA-4 and its ligand B7 (CD80 or CD86) effectively, thereby activates T-lymphocyte and inhibits the growth of tumor.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With our outstanding capacity for innovative drug discovery, strong biotechnology R&D capability, and large-scale production capacity, we have successfully developed a drug candidate portfolio with global competitiveness and a well-structured research pipeline, which covers therapeutic areas including cancer, autoimmune, metabolic, and infectious diseases. Our innovative field spans cutting-edge therapeutic modalities, including mAbs, small-molecule drugs, ADCs, bsAb/msAb, fusion proteins, nucleic acid drugs and vaccines. Five of the company’s products have received marketing authorizations in China and international markets, one of which is toripalimab, China’s domestically developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 50 countries and regions including China, the US, and Europe.

With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs,” Junshi Biosciences is “In China, For Global.” The company currently employs more than 3,000 people worldwide. Headquartered in Shanghai, China, it has a business presence in multiple countries and regions around the world. For more information, please visit: http://www.junshipharma.com.

Junshi Biosciences Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in November 2026.

Stifel 2026 Healthcare Conference
Location: New York, NY
Date: Thursday, November 12, 2026
Time: 10:00–10:30 a.m. ET
Format: Presentation
Presenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen

Cell & Gene Leaders Live 2026
Location: The Shard, London, UK
Date: Sunday, November 15, 2026
Time: 3:15–4:00 p.m. GMT
Format: Panel discussion
Presenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen

A webcast of the Stifel presentation will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on LinkedIn and X.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contacts:

Investors:
Candice Masse
astr partners
candice.masse@astrpartners.com

Media:
Chris Clark
chris.clark@ocugen.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.